Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma.

K. Hamazaki, A. Gochi, N. Matsubara, M. Mori, K. Orita

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Fas antigen (ag) is a cell surface protein known to trigger apoptosis in a variety of cells upon specific antibody binding. On the other hand, Bcl-2 protein, an oncogene product located at the mitochondrial inner surface, prolongs cell survival by blocking apoptosis. In this study we examined the expression of Fas ag and bcl-2 protein in 17 cases of hepatocellular carcinoma (HCC) to determine their role on HCC. By flow cytometric analysis, mean (SD) value of the expression of Fas ag on hepatocytes derived from normal liver, diseased liver (chronic hepatitis or liver cirrhosis) and HCC was 5.8 (4.7)%, 10.3 (6.9)%, and 24.0 (18.2)%, respectively. Fas ag expression on hepatoma cells was significantly greater than normal and diseased liver cells. The expression of Bcl-2 protein in normal liver, diseased liver and HCC was 4.3 (8.5)%, 0.8 (2.5)% and 2.1 (3.4)%, respectively, and the difference was not significant. These results suggest that induction of apoptosis may be a possible therapy against HCC.

Original languageEnglish
Pages (from-to)227-230
Number of pages4
JournalActa Medica Okayama
Volume49
Issue number4
Publication statusPublished - Aug 1995

Fingerprint

CD95 Antigens
Liver
Hepatocellular Carcinoma
Liver Diseases
Proteins
Apoptosis
Oncogene Proteins
Chronic Hepatitis
Liver Cirrhosis
Hepatocytes
Cell Survival
Membrane Proteins
Cells
Antibodies

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Hamazaki, K., Gochi, A., Matsubara, N., Mori, M., & Orita, K. (1995). Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma. Acta Medica Okayama, 49(4), 227-230.

Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma. / Hamazaki, K.; Gochi, A.; Matsubara, N.; Mori, M.; Orita, K.

In: Acta Medica Okayama, Vol. 49, No. 4, 08.1995, p. 227-230.

Research output: Contribution to journalArticle

Hamazaki, K, Gochi, A, Matsubara, N, Mori, M & Orita, K 1995, 'Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma.', Acta Medica Okayama, vol. 49, no. 4, pp. 227-230.
Hamazaki K, Gochi A, Matsubara N, Mori M, Orita K. Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma. Acta Medica Okayama. 1995 Aug;49(4):227-230.
Hamazaki, K. ; Gochi, A. ; Matsubara, N. ; Mori, M. ; Orita, K. / Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma. In: Acta Medica Okayama. 1995 ; Vol. 49, No. 4. pp. 227-230.
@article{dcb66e5d2a5447cca5928804e30073e8,
title = "Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma.",
abstract = "Fas antigen (ag) is a cell surface protein known to trigger apoptosis in a variety of cells upon specific antibody binding. On the other hand, Bcl-2 protein, an oncogene product located at the mitochondrial inner surface, prolongs cell survival by blocking apoptosis. In this study we examined the expression of Fas ag and bcl-2 protein in 17 cases of hepatocellular carcinoma (HCC) to determine their role on HCC. By flow cytometric analysis, mean (SD) value of the expression of Fas ag on hepatocytes derived from normal liver, diseased liver (chronic hepatitis or liver cirrhosis) and HCC was 5.8 (4.7){\%}, 10.3 (6.9){\%}, and 24.0 (18.2){\%}, respectively. Fas ag expression on hepatoma cells was significantly greater than normal and diseased liver cells. The expression of Bcl-2 protein in normal liver, diseased liver and HCC was 4.3 (8.5){\%}, 0.8 (2.5){\%} and 2.1 (3.4){\%}, respectively, and the difference was not significant. These results suggest that induction of apoptosis may be a possible therapy against HCC.",
author = "K. Hamazaki and A. Gochi and N. Matsubara and M. Mori and K. Orita",
year = "1995",
month = "8",
language = "English",
volume = "49",
pages = "227--230",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - Expression of Fas antigen and Bcl-2 protein in hepatocellular carcinoma.

AU - Hamazaki, K.

AU - Gochi, A.

AU - Matsubara, N.

AU - Mori, M.

AU - Orita, K.

PY - 1995/8

Y1 - 1995/8

N2 - Fas antigen (ag) is a cell surface protein known to trigger apoptosis in a variety of cells upon specific antibody binding. On the other hand, Bcl-2 protein, an oncogene product located at the mitochondrial inner surface, prolongs cell survival by blocking apoptosis. In this study we examined the expression of Fas ag and bcl-2 protein in 17 cases of hepatocellular carcinoma (HCC) to determine their role on HCC. By flow cytometric analysis, mean (SD) value of the expression of Fas ag on hepatocytes derived from normal liver, diseased liver (chronic hepatitis or liver cirrhosis) and HCC was 5.8 (4.7)%, 10.3 (6.9)%, and 24.0 (18.2)%, respectively. Fas ag expression on hepatoma cells was significantly greater than normal and diseased liver cells. The expression of Bcl-2 protein in normal liver, diseased liver and HCC was 4.3 (8.5)%, 0.8 (2.5)% and 2.1 (3.4)%, respectively, and the difference was not significant. These results suggest that induction of apoptosis may be a possible therapy against HCC.

AB - Fas antigen (ag) is a cell surface protein known to trigger apoptosis in a variety of cells upon specific antibody binding. On the other hand, Bcl-2 protein, an oncogene product located at the mitochondrial inner surface, prolongs cell survival by blocking apoptosis. In this study we examined the expression of Fas ag and bcl-2 protein in 17 cases of hepatocellular carcinoma (HCC) to determine their role on HCC. By flow cytometric analysis, mean (SD) value of the expression of Fas ag on hepatocytes derived from normal liver, diseased liver (chronic hepatitis or liver cirrhosis) and HCC was 5.8 (4.7)%, 10.3 (6.9)%, and 24.0 (18.2)%, respectively. Fas ag expression on hepatoma cells was significantly greater than normal and diseased liver cells. The expression of Bcl-2 protein in normal liver, diseased liver and HCC was 4.3 (8.5)%, 0.8 (2.5)% and 2.1 (3.4)%, respectively, and the difference was not significant. These results suggest that induction of apoptosis may be a possible therapy against HCC.

UR - http://www.scopus.com/inward/record.url?scp=0029349293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029349293&partnerID=8YFLogxK

M3 - Article

C2 - 7502684

AN - SCOPUS:0029349293

VL - 49

SP - 227

EP - 230

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -